BioPorto Diagnostics - Key leadership changes announced
BioPorto has announced the appointment of Anthony Pare and Neil Goldman as its new CEO and CFO, respectively, with effect from mid-November 2021....
292 Views
BioPorto Diagnostics - Focused on the upcoming paediatric AKI results
BioPorto has reported its results for Q121, which included DKK5.6m in sales from all its research use only products. This is up from Q120 (DKK4.2m)...
434 Views
Video: BioPorto – executive interview
BioPorto is a Denmark-based in vitro diagnostics company that uses antibody and assay expertise to transform novel research tools into clinically...
697 Views
BioPorto Diagnostics - Record setting NGAL sales
BioPorto reported a major increase in Q220 sales for the NGAL research use only (RUO) test, to DKK5.0m, up from DKK3.8m in Q219. This is the single...
176 Views
BioPorto Diagnostics - COVID-19 delays clinical studies
BioPorto announced in its Q120 earnings update that the timeline for submission of its paediatric NGAL Test would be delayed to H220 (from previous...
193 Views
No more insights